Related Experiment Video
Updated: Aug 17, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
The prognostic value of clinical and laboratory parameters in patients with chronic lymphocytic leukemia
I Nenova1, N Mateva, N Ananoshtev
1Department of Hematology, University Hospital, Medical University, 15A V. Aprilov Blvd, 4002, Plovdiv, Bulgaria.
Insights
Identifying prognostic factors for chronic lymphocytic leukemia (CLL) survival is crucial. Rai stage, performance status, and treatment response significantly impact patient outcomes in CLL.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Chronic lymphocytic leukemia (CLL) exhibits variable clinical progression.
- Accurate prognostic indicators are essential for effective patient management.
Purpose of the Study:
- To identify clinical and laboratory parameters predicting survival in CLL patients.
- To establish prognostic markers for better patient stratification.
Main Methods:
- Survival analysis of 131 CLL patients (1992-2003) using Kaplan-Meier and log-rank tests.
- Evaluation of prognostic value for parameters including Rai stage, ECOG PS, FAB type, and treatment response.
Main Results:
- Mean survival was 76 months.
- Significant prognostic factors identified: Rai clinical stage, ECOG Performance Status (PS), mediastinal lymphadenopathy, extranodal localization, FAB morphological type, and response to initial therapy.
Conclusions:
- Identified prognostic factors are clinically applicable.
- These factors can inform the development of mathematical prognostic models for CLL.
Purpose:
Chronic lymphocytic leukemia (CLL) is heterogeneous in its clinical course. The aim of the present study was to identify some clinical and laboratory parameters with prognostic value in relation to survival of patients with CLL.
Patients And Methods:
One hundred thirty one patients with CLL, treated in the Clinic of Hematology, Plovdiv, between 1992 and 2003 were studied. The patients' survival was analyzed by using the Kaplan-Meier method. Log-rank test was used to compare cumulative survival functions between different groups of patients. The parameters studied were: age, sex, Rai clinical stage, ECOG Performance status (PS), FAB morphological type, mediastinal lymphadenopathy, abdominal nodal mass, extranodal localization, absolute lymphocyte count, autoimmune hemolytic anemia, and response to therapy.
Results:
The mean survival of patients was 76 months (95% Confidence Interval, 64-87). The following factors were found to carry significant prognostic value in relation to survival: Rai clinical stage, ECOG PS, mediastinal lymphadenopathy, extranodal localization, FAB morphological type and response to initial standard treatment.
Conclusion:
The prognostic factors identified in the present study can be easily applied in the clinical practice and may be used as a basis for creating mathematical prognostic models.
